학술논문
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Document Type
Article
Author
Source
Anti-Cancer Agents in Medicinal Chemistry; July 2017, Vol. 17 Issue: 8 p1040-1045, 6p
Subject
Language
ISSN
18715206
Abstract
Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton’s tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.